Cell cycle arrest in ovarian cancer cell lines does not depend on p53 status upon treatment with cytostatic drugs

International Journal of Oncology

Volumn 13, Issue 5, 1998, Pages 1007-1016

  Merlin, Thomas ^a   Brandner, Gerhard ^a   Hess, Ralf D ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Apoptosis; Cell cycle arrest; Cisplatin; Cytostatic drags; Etoposide; Gemcitabine; Ovarian cancer cells; p53 accumulation; Taxol

Indexed keywords

CISPLATIN; CYTOSTATIC AGENT; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE G2 PHASE; CELL NUCLEUS; CYTOSTASIS; DNA DAMAGE; DOSE RESPONSE; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOSIS INHIBITION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REPORTER GENE;

EID: 0031732545     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.5.1007     Document Type: Article

References (48)

1. Ozols RF, Hamilton TC, Reed E, Poirier MC, Masuda H, Lai G and Young RC: High dose cisplatin and drug resistance: clinical and laboratory correlations. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Nicolini M (ed). Martinus Nijhoff, Boston, pp197-206, 1988.
2. Wenderlein JM: Ovarialkarzinom: das prognostisch ungünstigste Genitalkarzinom. Dt Ärztebl 86: 834-835, 1989.
3. Bosl G, Yagoda A, Golbey RB, Whitmore W Jr, Herr H, Sogani P, Morse M, Vogelzang N and MacDonald G: Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors. Am J Med 78: 423-428, 1985.
4. Peters HD, Blatter J and Ermisch S: Gemcitabin: pharmakologischcs Profil und klinische Anwendung. Onkologe 1: 367-382, 1995.
5. Yaginuma Y and Westphal H: Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52: 4196-4199, 1992.
6. Berchuck A, Kohler M, Marks JR, Wisemann R, Boyd J and Bast RC Jr: The p53 tumor suppressor gene frequently altered in gynecologic cancers. Am J Obstet Gynecol 170: 246-252, 1994.
7. Liebermann DA, Hoffman B and Steinman RA: Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 11: 199-210, 1995.
8. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
9. Stewart N, Hicks GG, Paraskevas F and Mowat M: Evidence for a second cell cycle block at G2/M by p53. Oncogene: 10: 109-115, 1995.
10. Siegel J, Fritsche M, Mai S, Brandner G and Hess RD: Enhanced p53 activity and accumulation in response to DNA damage upon DNA transfection. Oncogene 11: 1363-1370, 1995.
11. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B and Liebermann DA: p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene 10: 2263-2270, 1995.
12. Plaumann B, Fritsche M, Rimpler H, Brandner G and Hess RD: Flavonoids activate wild-type p53. Oncogene 13: 1605-1614, 1996.
13. Abrahamson JLA, Lee JM and Bernstein A: Regulation of p53-mediated apoptosis and cell cycle arrest by steel factor source. Mol Cell Biol 15: 6953-6960, 1995.
14. Maltzman W and Czykczyk L: UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4: 1689-1694, 1984.
15. Fritsche M, Haesslcr C and Brandncr G: Nuclear accumulation of p53: an indicator for chromatin injury? J Cancer Res Clin Oncol 117:53, 1991.
16. Fritsche M, Haessler C and Brandner G: Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307-318, 1993.
17. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
18. Hess R, Plaumann B, Schulze Lutum A, Haessler C, Heinz B, Fritsche M and Brandner G: Nuclear accumulation of p53 in response to treatment with DNA damaeing agents. Toxicol Lett 72:43-52, 1994.
19. Tishler RB, Calderwood SK, Coleman CN and Price BD: Increases in sequence-specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 53: 2212-2216, 1993.
20. Tishler RB, Lamppu DM, Park S and Price BD: Microtubuleactive drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res 55: 6021-6025, 1995.
21. Geisinger KR, Kute TE and Pettenati MJ: Characterization of a human ovarian carcinoma cell line with Estrogen and Progesterone receptors. Cancer 63: 280-288, 1989.
22. Buick RN, Pullano R and Trent JM: Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 45: 3668-3676, 1985.
23. Vikhanskaya F, Erba E, D'Incalci M and Broggini M: Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res 22: 1012-1017, 1994.
24. Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ and Thomas G: Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonie cancer patients and a control population. Hum Genet 86: 369-370, 1991.
25. Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF and Hamilton TC: Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res 54: 5911-5916, 1994.
26. Harlow E, Crawford LV, Pim DC and Williamson NM: Monoclonal antibodies specific for simian virus 40 tumor antigens. J Virol 39: 861-869, 1981.
27. Juven T, Barak Y, Zauberman A, George DL and Oren M: Wild-type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8: 3411-3416, 1993.
28. Barak Y, Juven T, Haffner R and Oren M: mdm2 expression is induced by wild-type p53 activity. EMBO J 12: 461-468, 1993.
29. Ostrup Jensen P, Laresen JK, Christensen IJ and van Erp PET: Discrimination of bromodeoxyuridine labelled and unlabelled mitotic cells in flow cytometric bromodeoxyuridine/DNA analysis. Cytometry 15: 154-161, 1994.
30. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
31. Agarwal ML, Agarwal A, Taylor WR and Stark GR: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible groth arrest in human fibroblasts. Proc Natl Acad Sci USA 92: 8493-8497, 1995.
32. Michieli P, Chedid M, Lin D, Pierce JD, Mercer WE and Givol D: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391-3395, 1994.
33. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B and Jacks T: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9: 935-944, 1995.
34. Graniela-Sire EA, Vikhanskaya F and Broggini M: Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. Ann Oncol 6: 589-593, 1995.
35. Johnson M, Dimitrov D, Vojta PJ, Barrett JC, Noda A, Pereira-Smith OM and Smith JR: Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinogenesis 11: 59-64, 1994.
36. Wyllie FS, Haughton MF, Bond JA, Rowson JM, Jones JJ and Wynford-Thomas D: S phase cell-cycle arrest following DNA damage is independent of the p53/p21WAF1 signalling pathway. Oncogene 12: 1077-1082, 1996.
37. Cote RJ, Esrig D, Groshen S, Jones PA and Skinner DG: p53 and treatment of bladder cancer. Nature 385: 123-124, 1997.
38. Lowe SW and Jacks T: Scientific correspondence. Nature 385: 124-125, 1997.
39. Kawasaki T, Tomita Y, Bilim V, Takeda M, Takahashi K and Kumanishi T: Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alteration. Int J Cancer 68:501-501, 1996.
40. Wafl and p53 requires c-raf-1. Cancer Res 55: 4623-4626, 1995.
41. Yonish-Rouach E, Deguin V, Zaitchouk T, Breugnot C, Mishal Z, Jenkins JR and May E: Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. Oncogene 12: 2197-2205, 1996.
42. Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
43. Chen C-Y, Oliner JD, Zhan Q, Fornace AJ, Vogelstein B and Kastan MB: Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 91: 2684-2688, 1994.
44. Lu X, Burbidge SA, Griffin S and Smith HM: Discordance between accumulated p53 protein level and its transcriptional activity in response to U.V. radiation. Oncogene 13: 413-418, 1996.
45. Hess RD and Brandner G: DNA-damagc-inducible p53 activity p53 in SV40-transformed cells. Oncogene 15: 2501-2504, 1997.
46. Caelles C, Helmbcrg A and Karin M: p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223, 1994.
47. Choisy-Rossi C and Yonish-Rouach E: Apoptosis and the cell cycle: the p53 connection. Cell Death Differ 5: 129-131, 1998.
48. Wieczorek AM, Watermann JLF, Watermann MJF and Halazonctis TD: Structure-based rescue of common tumor-derived p53 mutants. Nat Med 2: 1143-1146, 1996.